McKesson Corporation Acquires Proventys' Advanced Decision Support Assets in Oncology
(firmenpresse) - NEWTON, MA -- (Marketwire) -- 02/03/12 -- Proventys, a leading developer of personalized decision support technologies for oncology and cardiology, announced that McKesson Corporation has acquired its CDS Oncology assets.
"Proventys is very proud of the innovative offerings we developed to advance cancer care through the use of smart technologies that facilitate more personalized, evidence-based treatment for patients," said Ralph Snyderman, MD, Proventys' founder and chairman.
Proventys was founded to support the ability of physicians to deliver personalized medicine at the point of clinical care. The Company created software-based predictive and prognostic tests (PDx), including one to assess adverse outcomes of cancer chemotherapy. It also developed a state-of-the-art clinical decision support system (CDS), in collaboration with the National Comprehensive Cancer Network (NCCN), to provide the best standards of care for patients with cancer.
About Proventys
Proventys is a healthcare technology company that provides innovative decision support solutions to help clinicians optimize care for patients on a personalized basis. The Company developed a novel, web-based decision support system that dynamically renders guidelines, customizable clinical pathways and payer-specific coverage policies, presenting clinicians with relevant treatment options based on individual patient characteristics. In addition, the Company pioneered the creation of software-based predictive tests (PDx) to help clinicians assess a patient's personalized risk of a specific clinical event and guide appropriate care decisions. The Company's first PDx product candidate, currently under FDA review (de novo), was designed to help oncologists assess a patient's risk of febrile neutropenia, a common and serious complication of chemotherapy. Proventys is dedicated to aligning the interests of patients, providers and payers by offering solutions that personalize care and improve outcomes.
Contact:
G. Steven Burrill
Burrill & Company
(415) 591-5400
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2012 - 07:45 Uhr
Sprache: Deutsch
News-ID 1079330
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEWTON, MA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 111 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"McKesson Corporation Acquires Proventys' Advanced Decision Support Assets in Oncology
"
steht unter der journalistisch-redaktionellen Verantwortung von
Proventys (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
